Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 13/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | BCR | P11274 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15142441 | 0.80 | AXL (0.35) | MDM2KDM4EALDH1A1HTTHPGD | |
| SCHEMBL6607812 | 0.79 | NPC1 (0.38) | KDM4EALDH1A1HTTHPGD | |
| SCHEMBL12467200 | 0.79 | PGK1 (0.40) | KDM4EALDH1A1HTTHPGD | |
| SCHEMBL30716907 | 0.79 | NPC1 (0.38) | KDM4EALDH1A1HTTHPGD | |
| SCHEMBL6608302 | 0.78 | KDM4E (0.36) | MDM2TP53KDM4EALDH1A1HTT | |
| SCHEMBL6606573 | 0.75 | PDE3B (0.36) | SRC | |
| SCHEMBL6606814 | 0.74 | MDM2 (0.32) | MDM2TP53KDM4EALDH1A1HTT | |
| SCHEMBL28015248 | 0.72 | NPC1 (0.42) | KDM4EALDH1A1HPGD | |
| SCHEMBL24529326 | 0.72 | HTR1A (0.43) | TP53KDM4EALDH1A1 | |
| SCHEMBL15142051 | 0.72 | GAA (0.42) | KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3272754-B1 | IMIDAZOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2019-05-29 | — | — | EP | disclosed |
| EP-3272754-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | Novartis AG (CH) | 2018-01-24 | — | — | EP | disclosed |
| EP-3064502-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | Novartis AG (CH) | 2016-09-07 | — | — | EP | disclosed |
| CN-104203952-A | Imidazopyrrolidinone compounds | NOVARTIS AG | 2014-12-10 | — | — | CN | disclosed |
| EP-2807164-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | Novartis AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| US-20140343084-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2014-11-20 | — | — | US | disclosed |
| US-8815926-B2 | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases | NOVARTIS AG (CH) | 2014-08-26 | — | — | US | disclosed |
| US-20140011798-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2014-01-09 | — | — | US | disclosed |
| WO-2013111105-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2013-08-01 | — | — | WO | disclosed |
| EP-0882714-B1 | SUBSTITUTED VINYLPYRIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME | SS PHARMACEUTICAL CO (JP) | 2004-03-03 | — | — | EP | disclosed |
| US-5935977-A | PHOSPHODIESTERASE IV INHIBITORS, TUMOR NECROSIS FACTOR-ALPHA PRODUCTION INHIBITORS; TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES | SS PHARMACEUTICAL CO., LTD. (JP) | 1999-08-10 | — | — | US | disclosed |
| EP-0882714-A1 | SUBSTITUTED VINYLPYRIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME | SS Pharmaceutical Co., Ltd. (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011798-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | MDM4, MDM2, TP53 | MDM2 2/4885TP53 3/4885SRC 2040/4885 |
| US-20140343084-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | MDM4, MDM2, TP53 | MDM2 2/4885TP53 3/4885SRC 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.